Registered title, quoted from ClinicalTrials.gov
Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
An open trial on amyotrophic lateral sclerosis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06671236, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Serum creatinine less than or equal to 2.0 mg/dL;
Inclusion criterion 6
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal;
Inclusion criterion 7
Bilirubin < 1.5 (except Gilbert's disease);
Inclusion criterion 8
Seropositive for HIV, hepatitis B or hepatitis C;
Exclusion criterion 6
Pregnant or lactating patients;
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06671236, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
-
Patients must meet all of the following criteria to be eligible for enrollment in this study:
- Male or female patients aged 18 to 70 years;
- According to current international diagnostic criteria:
ALS: defined by the Gold Coast Diagnostic Criteria (Shefner, 2020) as having a diagnosis of sporadic or familial amyotrophic lateral sclerosis (ALS), diagnosed as a probable, probable, or definite patient with laboratory support according to the World Federation of Neurology El Escorial criteria;
- If there is a stable dose for more than one month prior to study entry. For example, patients with ALS can continue treatment with riluzole (Rilutek®) and/or edaravone (Radicava®);
- Patients must have > two weeks after the end of major surgery and after the completion of participation in other research trials;
- Patients must have recovered from clinical toxicity (CTCAE [5th Edition] toxicity values have resolved to < 2);
- Serum creatinine less than or equal to 2.0 mg/dL;
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal;
- Bilirubin < 1.5 (except Gilbert's disease);
- Lung slow vital capacity (SVC) > 70% of predicted normal;
- No history of abnormal bleeding tendency;
- Informed consent must be obtained prior to performing any study-related procedures that are not part of standard medical care, with the understanding that the participant may withdraw from the study without influence for the future medical care.
Exclusion Criteria:
-
Subjects with any of the following cannot be enrolled in this study:
- uncontrolled infection;
- < 3 drugs do not adequately control hypertension;
- Documented history of pulmonary embolism within 6 months of enrollment;
- Clinically significant cardiology, defined as: myocardial infarction, NYHA-graded class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia, or ECG evidence of acute ischemia or abnormal conduction system within 6 months prior to enrollment;
- Patients with a history of coronary artery bypass grafting or angioplasty will be evaluated by cardiology and considered on a case-by-case basis;
- Seropositive for HIV, hepatitis B or hepatitis C;
- Pregnant or lactating patients;
- Patients of childbearing potential or males with partners of childbearing potential who are unwilling to use contraception;
- Participation in any other interventional study;
- Treatment with another investigational drug, biologic, or device within 30 days or 5 half-lives (whichever is longer) of the screening period. Patient participation in observational/non-interventional clinical studies will be discussed with the Medical Monitor;
- Prior treatment with ALS gene or cell therapy;
- History of clinically significant tumor, liver or kidney disease, or other uncontrolled disease;
- presence of a feeding tube;
- Current use of antipsychotics, antiepileptic drugs (except benzodiazepines, gabapentin, pre-Bahrain) or class 1 (e.g., flecainide) or class 3 (e.g., amiodarone) antiarrhythmic drugs;
- Subjects who, in the opinion of the investigator, are at significant risk of suicide;
- Other conditions that the investigator considers unsuitable for enrollment.
Quoted from ClinicalTrials.gov, NCT06671236, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06671236, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.